<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Launch One Acquisition Corp. Unit — News on 6ix</title>
    <link>https://6ix.com/company/launch-one-acquisition-corp-unit</link>
    <description>Latest news and press releases for Launch One Acquisition Corp. Unit on 6ix.</description>
    <language>en-us</language>
    <lastBuildDate>Tue, 13 Jan 2026 05:00:00 GMT</lastBuildDate>
    <generator>6ix RSS</generator>
    <atom:link href="https://6ix.com/rss/company/launch-one-acquisition-corp-unit" rel="self" type="application/rss+xml" />
    <item>
      <title>Minovia Therapeutics Announces Two New U.S. Patents Granted, Strengthening Its Mitochondrial Augmentation Therapy Platform</title>
      <link>https://6ix.com/company/launch-one-acquisition-corp-unit/news/minovia-therapeutics-announces-two-new-us-patents-granted-strengthening-its-mitochondrial-augmentation-therapy-platform-1</link>
      <guid isPermaLink="true">https://6ix.com/company/launch-one-acquisition-corp-unit/news/minovia-therapeutics-announces-two-new-us-patents-granted-strengthening-its-mitochondrial-augmentation-therapy-platform-1</guid>
      <pubDate>Tue, 13 Jan 2026 05:00:00 GMT</pubDate>
      <description>New U.S. intellectual property protections expand use of Minovia’s leading technology in mitochondrial-based therapies for primary mitochondrial and severe</description>
    </item>
    <item>
      <title>Minovia Therapeutics Mitochondrial Augmentation Technology to be Featured in Presentation and Workshop at the 67th ASH Annual Meeting and Exposition</title>
      <link>https://6ix.com/company/launch-one-acquisition-corp-unit/news/minovia-therapeutics-mitochondrial-augmentation-technology-to-be-featured-in-presentation-and-workshop-at-the-67th-ash-annual-meeting-and-exposition-1</link>
      <guid isPermaLink="true">https://6ix.com/company/launch-one-acquisition-corp-unit/news/minovia-therapeutics-mitochondrial-augmentation-technology-to-be-featured-in-presentation-and-workshop-at-the-67th-ash-annual-meeting-and-exposition-1</guid>
      <pubDate>Thu, 20 Nov 2025 05:00:00 GMT</pubDate>
      <description>Results from pre-clinical studies conducted by scientists at Memorial Sloan Kettering Cancer Center show delayed leukemic progression and improved survival;</description>
    </item>
    <item>
      <title>Minovia Therapeutics Receives FDA Orphan Drug Designation for MNV-201 in Myelodysplastic Syndrome</title>
      <link>https://6ix.com/company/launch-one-acquisition-corp-unit/news/minovia-therapeutics-receives-fda-orphan-drug-designation-for-mnv-201-in-myelodysplastic-syndrome-1</link>
      <guid isPermaLink="true">https://6ix.com/company/launch-one-acquisition-corp-unit/news/minovia-therapeutics-receives-fda-orphan-drug-designation-for-mnv-201-in-myelodysplastic-syndrome-1</guid>
      <pubDate>Wed, 15 Oct 2025 04:00:00 GMT</pubDate>
      <description>Regulatory Milestone Adds to Fast-Track Designation Providing Further Potential Regulatory Advantages as Company Develops First-in-Class Mitochondrial Cell</description>
    </item>
    <item>
      <title>Minovia Therapeutics Receives FDA Fast Track Designation for MNV-201 in Myelodysplastic Syndrome</title>
      <link>https://6ix.com/company/launch-one-acquisition-corp-unit/news/minovia-therapeutics-receives-fda-fast-track-designation-for-mnv-201-in-myelodysplastic-syndrome-1</link>
      <guid isPermaLink="true">https://6ix.com/company/launch-one-acquisition-corp-unit/news/minovia-therapeutics-receives-fda-fast-track-designation-for-mnv-201-in-myelodysplastic-syndrome-1</guid>
      <pubDate>Thu, 18 Sep 2025 04:00:00 GMT</pubDate>
      <description>Regulatory Milestone Underscores Continued Promise of First-in-Class Mitochondrial Cell Therapy HAIFA, Israel, Sept. 18, 2025 (GLOBE NEWSWIRE) -- Minovia</description>
    </item>
    <item>
      <title>Minovia Therapeutics Announces $350,000 Grant from Countdown for a Cure Foundation to Develop Mitochondria Blood-Based Biomarkers</title>
      <link>https://6ix.com/company/launch-one-acquisition-corp-unit/news/minovia-therapeutics-announces-dollar350000-grant-from-countdown-for-a-cure-foundation-to-develop-mitochondria-blood-based-biomarkers-1</link>
      <guid isPermaLink="true">https://6ix.com/company/launch-one-acquisition-corp-unit/news/minovia-therapeutics-announces-dollar350000-grant-from-countdown-for-a-cure-foundation-to-develop-mitochondria-blood-based-biomarkers-1</guid>
      <pubDate>Wed, 27 Aug 2025 04:00:00 GMT</pubDate>
      <description>HAIFA, Israel, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Minovia Therapeutics Ltd. (“Minovia” or the “Company”), a clinical-stage biotechnology company developing</description>
    </item>
    <item>
      <title>Minovia Therapeutics Announces Interim Data from Phase 2 Trial in Pearson Syndrome Demonstrating No Treatment-Related Serious Adverse Events and Preliminary Signal for Efficacy Measured by Growth</title>
      <link>https://6ix.com/company/launch-one-acquisition-corp-unit/news/minovia-therapeutics-announces-interim-data-from-phase-2-trial-in-pearson-syndrome-demonstrating-no-treatment-related-serious-adverse-events-and-preliminary-signal-for-efficacy-measured-by-growth-1</link>
      <guid isPermaLink="true">https://6ix.com/company/launch-one-acquisition-corp-unit/news/minovia-therapeutics-announces-interim-data-from-phase-2-trial-in-pearson-syndrome-demonstrating-no-treatment-related-serious-adverse-events-and-preliminary-signal-for-efficacy-measured-by-growth-1</guid>
      <pubDate>Thu, 24 Jul 2025 04:00:00 GMT</pubDate>
      <description>Data presented at the UMDF meeting highlighting first three of expected six subjects and two compassionate use patients provide encouraging results supporting</description>
    </item>
    <item>
      <title>Minovia Therapeutics Announces FDA Fast Track and Rare Pediatric Disease Designations for MNV-201 in Pearson Syndrome</title>
      <link>https://6ix.com/company/launch-one-acquisition-corp-unit/news/minovia-therapeutics-announces-fda-fast-track-and-rare-pediatric-disease-designations-for-mnv-201-in-pearson-syndrome-1</link>
      <guid isPermaLink="true">https://6ix.com/company/launch-one-acquisition-corp-unit/news/minovia-therapeutics-announces-fda-fast-track-and-rare-pediatric-disease-designations-for-mnv-201-in-pearson-syndrome-1</guid>
      <pubDate>Mon, 30 Jun 2025 04:00:00 GMT</pubDate>
      <description>Regulatory Milestone Underscores Urgency and Promise of First-in-Class Mitochondrial Cell Therapy Haifa, ISRAEL, June 30, 2025 (GLOBE NEWSWIRE) -- Minovia</description>
    </item>
    <item>
      <title>Minovia Therapeutics Ltd. and Launch One Acquisition Corp. Announce Proposed Business Combination to Create Nasdaq-Listed Mitochondrial Therapy Company in $1 Trillion+ Mitochondrial and Longevity Markets</title>
      <link>https://6ix.com/company/launch-one-acquisition-corp-unit/news/minovia-therapeutics-ltd-launch-one-123000200-1</link>
      <guid isPermaLink="true">https://6ix.com/company/launch-one-acquisition-corp-unit/news/minovia-therapeutics-ltd-launch-one-123000200-1</guid>
      <pubDate>Wed, 25 Jun 2025 12:30:00 GMT</pubDate>
      <description>Minovia’s mitochondrial augmentation technology (MAT) targets multi-organ clinical benefits; lead program MNV-201 has both FDA Fast Track Designation and Rare Pediatric Disease designation and is preparing for its first pivotal clinical trialHAIFA, Israel, and GEORGE TOWN, Cayman Islands, June 25, 2025 (GLOBE NEWSWIRE) -- Minovia Therapeutics Ltd. (“Minovia” or the “Company”), a clinical-stage biotechnology company developing what it believes to be first-in-class therapies to treat mitochondrial</description>
    </item>
    <item>
      <title>Launch One Acquisition Corp. I Announces the Separate Trading of its Class A Ordinary Shares and Warrants, Commencing September 3, 2024</title>
      <link>https://6ix.com/company/launch-one-acquisition-corp-unit/news/launch-one-acquisition-corp-i-announces-the-separate-trading-of-its-class-a-ordinary-shares-and-warrants-commencing-september-3-2024</link>
      <guid isPermaLink="true">https://6ix.com/company/launch-one-acquisition-corp-unit/news/launch-one-acquisition-corp-i-announces-the-separate-trading-of-its-class-a-ordinary-shares-and-warrants-commencing-september-3-2024</guid>
      <pubDate>Thu, 29 Aug 2024 04:00:00 GMT</pubDate>
      <description>New York, NY, Aug. 29, 2024 (GLOBE NEWSWIRE) -- Launch One Acquisition Corp. (Nasdaq: LPAAU) (the “Company”) announced today that, commencing September 3,</description>
    </item>
    <item>
      <title>Launch One Acquisition Corp. Completes $230.0 Million Initial Public Offering</title>
      <link>https://6ix.com/company/launch-one-acquisition-corp-unit/news/launch-one-acquisition-corp-completes-dollar2300-million-initial-public-offering</link>
      <guid isPermaLink="true">https://6ix.com/company/launch-one-acquisition-corp-unit/news/launch-one-acquisition-corp-completes-dollar2300-million-initial-public-offering</guid>
      <pubDate>Mon, 15 Jul 2024 04:00:00 GMT</pubDate>
      <description>NEW YORK, NY, July 15, 2024 (GLOBE NEWSWIRE) -- Launch One Acquisition Corp. (the “Company”) announced today the closing of its initial public offering of</description>
    </item>
  </channel>
</rss>